ZIA CP010131-04134 (ZIA) | |||
---|---|---|---|
Title | Radiation dose- response and second primary cancers of stomach, esophagus, and | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Morton, Lindsay | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $96,661 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Cancer Survivorship (100.0%) Chemotherapy (100.0%) |
Breast (8.0%) Cervical Cancer (7.0%) Esophagus (15.0%) Hodgkins disease (15.0%) Pancreas (15.0%) Stomach (20.0%) Testes (10.0%) |
||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors |
|||
Abstract | |||
"""REB is leading a multicenter international study of second primary gastrointestional (GI) cancers among survivors of Hodgkin lymphoma and cancers of the testis, breast and cervix. This series of seven nested case-control studies, with detailed radiotherapy and chemotherapy treatment data, represents the first comprehensive effort outside of the studies of atomic bomb survivors to quantify the radiation dose-response relationship for upper-GI cancers. Additionally, the study provides novel information about solid tumor risks in relation to type and dose of chemotherapy agents. Findings to date include a demonstrated increased stomach cancer risk after Hodgkin lymphoma with increasing radiation dose to the stomach and with increasing number of alkylating agent-containing chemotherapy cycles. Patients who received both 25+ Gy radiation to the stomach and high-dose (5600+ mg/m2) procarbazine had multiplicatively increased stomach cancer risk (OR=77.5). Additional findings from the series of studies included radiation-related increased stomach cancer risk after testicular and cervical cancers, radiation-related increased esophageal cancer risk after Hodgkin lymphoma, and radiation- and chemotherapy-related increased pancreatic cancer risk after Hodgkin lymphoma. REB dosimetrists described the patterns of radiation dose to the esophagus from breast cancer radiotherapy over the last several decades, and derived a method to better characterize the variability in the stomach size, shape, and location for radiation dose.""" |